Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics Inc.

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics today and set a price target of $130.00. Slutsky covers the He...

Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital

Chardan Capital analyst Geulah Livshits maintained a Buy rating on Palvella Therapeutics yesterday and set a price target of $110.00. Livshits cove...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$94.09	+2.79%	232.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$94.09	+2.8%	232.89K
3
4
5
6

PVLA

PVLA

Dividend Overview

Get Palvella Therapeutics Inc. Data in Excel

Get Palvella Therapeutics Inc. Data in Excel